This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tazemetostat
Accession Number
DB12887
Type
Small Molecule
Groups
Investigational
Description

Tazemetostat has been used in trials studying the treatment of Rhabdoid Tumors, Synovial Sarcoma, Epithelioid sarcoma, INI1-negative Tumors, and Renal Medullary Carcinoma, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
EPZ-6438
Categories
UNII
Q40W93WPE1
CAS number
1403254-99-8
Weight
Average: 572.75
Monoisotopic: 572.336255913
Chemical Formula
C34H44N4O4
InChI Key
NSQSAUGJQHDYNO-UHFFFAOYSA-N
InChI
InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)
IUPAC Name
N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-[ethyl(oxan-4-yl)amino]-4-methyl-4'-[(morpholin-4-yl)methyl]-[1,1'-biphenyl]-3-carboxamide
SMILES
CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=C(CN2CCOCC2)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AHistone-lysine N-methyltransferase EZH2
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
66558664
PubChem Substance
347829042
ChemSpider
30208713
BindingDB
172038
ChEMBL
CHEMBL3414621

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Primary Mediastinal Lymphoma1
1Active Not RecruitingTreatmentINI1-negative Tumors / Malignant Rhabdoid Tumor of Ovary / Rhabdoid Tumors / Synovial Sarcoma1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma1
1RecruitingTreatmentAdvanced Solid Tumors / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Primary Mediastinal Lymphoma1
1SuspendedTreatmentAnn Arbor Stage III B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma / Liver Dysfunction / Metastatic Malignant Solid Neoplasm / Stage III B-Cell Non-Hodgkin Lymphoma / Stage III Hepatocellular Carcinoma AJCC v7 / Stage IIIA Hepatocellular Carcinoma AJCC v7 / Stage IIIB Hepatocellular Carcinoma AJCC v7 / Stage IIIC Hepatocellular Carcinoma AJCC v7 / Stage IV B-Cell Non-Hodgkin Lymphoma / Stage IV Hepatocellular Carcinoma AJCC v7 / Stage IVA Hepatocellular Carcinoma AJCC v7 / Stage IVB Hepatocellular Carcinoma AJCC v7 / Unresectable Solid Neoplasm1
1, 2RecruitingTreatmentAdvanced Solid Tumors (Phase 1) / B-cell Lymphomas (Phase 1) / Diffuse Large B-cell Lymphoma (Phase 2) / Follicular Lymphoma (Phase 2) / Primary mediastinal large B-cell lymphomas / Transformed Follicular Lymphoma1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2SuspendedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentBAP1 Loss of Function / Mesothelioma1
2Not Yet RecruitingTreatmentGrade 1 Endometrial Endometrioid Adenocarcinoma / Grade 2 Endometrial Endometrioid Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma1
2Not Yet RecruitingTreatmentRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma1
2RecruitingScreeningAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Childhood Langerhans Cell Histiocytosis / Histiocytic Sarcoma (HS) / Juvenile Xanthogranuloma / Langerhans Cell Histiocytosis (LCH) / Malignant Gliomas / Malignant Lymphomas / Recurrent Central Nervous System Neoplasm / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma / Recurrent Gliomas / Recurrent Hepatoblastoma / Recurrent Langerhans Cell Histiocytosis / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Peripheral Primitive Neuroectodermal Tumor / Refractory Central Nervous System Neoplasm / Refractory Childhood Malignant Germ Cell Tumor / Refractory Langerhans cell histiocytosis / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Rhabdoid Tumors / Stage III Childhood Non-Hodgkin Lymphoma / Stage III Osteosarcoma / Stage III Osteosarcoma AJCC v7 / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Childhood Non-Hodgkin Lymphoma / Stage IV Osteosarcoma / Stage IV Osteosarcoma AJCC v7 / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Stage IVA Osteosarcoma / Stage IVA Osteosarcoma AJCC v7 / Stage IVB Osteosarcoma / Stage IVB Osteosarcoma AJCC v7 / Wilms' tumor1
2RecruitingTreatmentAdvanced Solid Tumors / Atypical Teratoid Rhabdoid Tumors (ATRT) / Epitheliod Sarcoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Rhabdoid Tumors (MRT) / Mesothelioma / Rhabdoid Tumors of the Kidney (RTK) / Synovial Sarcoma1
2RecruitingTreatmentAny Solid Tumor With an EZH2 GOF Mutation / Atypical Teratoid Rhabdoid Tumors (ATRT) / Epithelioid Sarcoma / INI1-negative Tumors / Malignant Rhabdoid Tumor of Ovary / Malignant Rhabdoid Tumors (MRT) / Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval) / Renal Medullary Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Selected Tumors With Rhabdoid Features / Synovial Sarcoma1
2SuspendedTreatmentAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Hodgkin Lymphoma / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / EZH2 Gain of Function / EZH2 Gene Mutation / Histiocytosis / Loss of BRG1 Protein Expression / Loss of INI 1 Protein Expression / Low Grade Glioma (LGG) / Malignant Gliomas / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Ependymoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma / Recurrent Germ Cell Tumor / Recurrent Gliomas / Recurrent Hepatoblastoma / Recurrent Hodgkin Lymphoma / Recurrent Langerhans Cell Histiocytosis / Recurrent Malignant Germ Cell Tumor / Recurrent Malignant Gliomas / Recurrent Malignant Solid Neoplasm / Recurrent Medulloblastoma / Recurrent Neuroblastoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Osteosarcoma / Recurrent Peripheral Primitive Neuroectodermal Tumor / Recurrent Rhabdoid Tumor / Recurrent Rhabdomyosarcoma / Recurrent Soft Tissue Sarcoma / Refractory Central Nervous System Neoplasm / Refractory Hodgkin Lymphoma / Refractory Langerhans cell histiocytosis / Refractory Malignant Germ Cell Tumor / Refractory Malignant Glioma / Refractory Medulloblastoma / Refractory Neuroblastoma / Refractory Non-Hodgkin's lymphoma / Refractory Osteosarcoma / Refractory Peripheral Primitive Neuroectodermal Tumor / Refractory Rhabdoid Tumor / Refractory Soft Tissue Sarcoma / Rhabdoid Tumors / SMARCA4 Gene Inactivation / SMARCB1 Gene Inactivation / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Non-Hodgkin Lymphoma / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Non-Hodgkin Lymphoma / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Wilms' tumor1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00932 mg/mLALOGPS
logP4.44ALOGPS
logP3.45ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)11.64ChemAxon
pKa (Strongest Basic)7.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.14 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity171.5 m3·mol-1ChemAxon
Polarizability66.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Aminobenzamides / o-Toluamides / Benzamides / Benzoyl derivatives / Benzylamines / Phenylmethylamines / Dialkylarylamines / Aniline and substituted anilines / Aminotoluenes / Pyridinones
show 16 more
Substituents
Biphenyl / Aminobenzamide / Aminobenzoic acid or derivatives / Benzamide / Toluamide / O-toluamide / Benzoic acid or derivatives / Benzoyl / Benzylamine / Tertiary aliphatic/aromatic amine
show 36 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.
Specific Function
Chromatin binding
Gene Name
EZH2
Uniprot ID
Q15910
Uniprot Name
Histone-lysine N-methyltransferase EZH2
Molecular Weight
85362.435 Da

Drug created on October 20, 2016 19:01 / Updated on August 02, 2018 06:44